{"ticker": {"uuid": "7e404f25-d9c6-4c3a-851f-322aac015bbc", "symbol": "BTMD", "name": "biote Corp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Care Facilities"}, "articles": [{"title": "Price to earnings forward of Biote Corp. \u2013 NASDAQ:BTMD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPVVZCQWE1UWhmVXA1aHRjYUJfOU9aSW9HSFk2bUtCTUVOZGk4a0s0bmN3blE3ZUFraTYzVy1ZV3JUX2x1bFU0TVlKUjFxMFNoRjU4QWppU21XczVuLVZEeHpVemZDWkkzVTJSc2lnMU9tSjFVTHlvRFVjZzF5NGRxdllKSVpQcFA1Zk84S3NTUC11Y0wwUUVVZmZqSExBcHNmclE?oc=5", "source_name": "TradingView", "published_at": "2026-07-06T00:37:48+00:00", "published_display": "06 Jul 2026 00:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. (BTMD) Climbs 9% as Stock Rebounds From Support Level - Early Entry Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPSHhMYlRpTnlfZUpHX1JUcmtxYV9KMmNkbkN1NXpyaTg4Wk5iUGdnQ2wxSDlxWlIxYUU5eDl6SXFxRjdQM1dlRXN0VEVIeUt0bzZuMmx6cXdxRm9va2JzZXczZTZvQnNjc2tpR0VWRDlqMExQeU9Zblc4RHB4U1d1SE1CMjRKX0FOOUVINXNWLU9NYU5SOEVacG00UTVYQWNhMlZDQjM3MV9ZdjJ6?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. (BTMD) Climbs 9% as Stock Rebounds From Support Level - Thematic ETF Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOeGFHeWtQdTExWWtTaVQ0VlBNSVZrN3M5MWxXUURJWnNJb1FuU19MdGptcmMtMGtNVzJuUFBHdnVfeGc2ZUxtTzh5Z1pKZXZkUzdDTnBSX0w3UThZaHhYTEN4Z2cwdEt1X2FKUWREcnpqVU5PLWsxSHRiWm1BNWpQNzIwcHYwYlA0RE9wVDQyN3N4dEVnVzQ3Nm83WFVKQ0U4LTdWdjZR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp.(NasdaqGM: BTMD) dropped from Russell 2500 Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSDhfODViMTlfSmFRMzlCU3dQLW1GS2lBQXdPcWlvMEVubnVwSjlBc01ESlBNc25WdDg3Q0lUM3cwTF83TXRYbUhDdzJlQzl0TzBVd2ZNNUFHemFSNTZIR18wSjN2QU9PTm5zTXZUYTk1S2Uwb05OX1FxaTdxRlI0U2QtQktTaHpuXzJJc0FmQTdnZWkwRFFHLUd2dnFVSUZqRnhFTjUwT0VXTjJTeVVRT3hSd0RhTUs4Z3ZN?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp.(NasdaqGM: BTMD) dropped from Russell 3000E Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPdnRGZUYwaV9mUEJtUkZoc0xOa3VOTl9makNOWW9tN2U5UWdXYnhsOC1XczhjYndBN0s3a042ZXlJck5nQklIeXQzVy0tSlJoajFIWTVXUGZSbEFHcThoRFNlYUpiQVc3TGhuZTJtc01qNEtjNW56VmJvNU1IMllYckVCekVmT2tkUW9uVjV6dm9fZ0FMRDJ4T3BEVTJaZkhpclFRVlFXQ3pXU0F4R2Rr?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp.(NasdaqGM: BTMD) dropped from Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOVUdCdHdTSm5kMXpXSUd3NEpfNV9WZjNsU3NjZmRqdVRZRU9PQTZ3YkNLQXNqQ1N3aFJuYmxUc25DSkw5LTR2SGNOTnc1ay14bXJMMTZHMFJwRUxJbHhFby1WczA0cS1tSE1SbDZOYXRocTZXaGZHZzkyNlNnTzg5WFNwMjdINDdJWWVMMFhJOHZERk1wYnlsZlFuUmowaEEweXdTNXR0M1prRDBtaTF6RnNKelkwTjBlbEJfTQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. Class A Actuals & Estimates (NASDAQ:BTMD)", "summary": "This article provides an overview of Biote Corp. (NASDAQ: BTMD) stock, including its current price, historical performance, analyst forecasts, volatility, market capitalization, and financial results. It details recent earnings and revenue, upcoming earnings dates, and confirms t", "url": "https://www.tradingview.com/symbols/NASDAQ-BTMD/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T06:41:16", "published_display": "26 Jun 2026 06:41", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. (BTMD) Holds Steady Near Support as Slight Decline Persists - IV Contraction", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNZzFCdWNrdWs3d3pvVm40ellVb2pXUm1GTEU3czM3ZGw1a1VVaGc4Q3owN0w2VG5TTWJyVjNidUlKQmlTdEZzWktLSTJMVTJ1bjdJcmVuVHZLNDBIMlJ0VEJCVGxXekZTaDRoV2xFTU5jTTBfTld2YUdiUERvMEZPUVlRaDRnYTJHTFNuVjhqZkNrLXVrQ0k3b1Q4cXUxNWstcTdZWXBVT2E5azJIMTQ3cXpn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) interim CEO receives 206,746 stock options at $2.46 strike", "summary": "biote Corp.'s interim CEO, Robert Charles Peterson, was granted 206,746 stock options with an exercise price of $2.46 per share, set to expire on June 11, 2036. The options will vest over time, with 25% vesting on June 12, 2027, and the remainder vesting in 36 equal monthly insta", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-a123b6448486.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:09:47", "published_display": "16 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. (BTMD) Slides 2.67% as Stock Tests Key Support Levels - Smart Beta Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQVGlnOUdCNWhsNDBFc1hidVlFVDVJTWpxd3JUVGMtU2EyWDBhenFxOFJReVYzcHpYTGRNa2dFNFRpUFU1R01JdmlHVE9UUVlSM3Q2ck1vemNJMXNfWG1yNGRFaHphU1hDOU5tZTJod0haWXVQa0h1SnJkOEFXNG83aElmX1J2WDRlMExEVGNRNUg3U2VPWngyXzNnLTdPSmpoRkdvRw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) director receives 130,000 stock options at $2.34 strike", "summary": "biote Corp. director Bret Christensen was granted 130,000 stock options with an exercise price of $2.34 per share, expiring on June 7, 2036. These options will vest on the earlier of June 8, 2027, or the day before the company's 2027 Annual Meeting, provided Christensen remains i", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-d3bcbfa18a04.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:10:31", "published_display": "10 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) Executive Chairman receives 114,157 stock options at $2.34", "summary": "biote Corp.'s Executive Chairman, Marc D. Beer, was granted 114,157 employee stock options with an exercise price of $2.34 per share, expiring on June 7, 2036. These options will vest over time, with 25% vesting on June 8, 2027, and the remaining 75% vesting in 36 equal monthly i", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-be47adcb08fa.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:10:31", "published_display": "10 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Evolving Story For biote (BTMD) May Shape Future Investor Expectations", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/evolving-story-biote-btmd-may-080607062.html", "source_name": "Simply Wall St.", "published_at": "2026-06-06T08:06:07+00:00", "published_display": "06 Jun 2026 08:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Announces Interim CEO Amid Leadership Transition Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPbUdaQnBLSUQ1OHZWcHZKZkxRLWNmYWdhWGZiTXlmX3FJQWdtcEdhczg2a3pmR3A5OE5QSzNzYmc5eHVYVWFVazZsYXdUN1ozY01TQVB6VUpDb1ZBWXVva19qY3k3ajlZXzBKQ18tMVFQZUZITFR6bU1fUFBjTW1WSXZ1S0JQNnhLeUpqNV9wNDZ6ZkhUX2pMZmdBRV9KcjFiTGdGUDZtb1JaU09hVnpMandXZ3d4MzlJZGttVFZnSXZ5Si1HZEVhRmE1SVhYZ1Z4UlJCRE1GaWs?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote (NASDAQ: BTMD) names interim CEO, appoints Executive Chairman and reaffirms 2026 outlook", "summary": "Biote (NASDAQ: BTMD) announced a leadership transition, naming Robert Peterson as Interim CEO and Marc Beer as Executive Chairman, following Bret Christensen's resignation for personal reasons. The company reaffirmed its full-year 2026 guidance, expecting revenue above $190 milli", "url": "https://www.stocktitan.net/sec-filings/BTMD/8-k-biote-corp-reports-material-event-07698fab733b.html", "source_name": "Stock Titan", "published_at": "2026-06-02T23:10:45", "published_display": "02 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/biote-appoints-komal-bajaj-md-120000439.html", "source_name": "Business Wire", "published_at": "2026-06-01T12:00:00+00:00", "published_display": "01 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NYC hospital quality chief Komal Bajaj becomes Biote CMO", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQWVQ4cmJDUzdnbHVEc2VjaXh0ZVJPUVRTWm05Yjl3UWlLYmgySEFkTDZ2MFFSaHZuRUxGMmhxTkYxcDdscnpRUlBicTcxYUVKa3ZFeC15Z0tWMFlxTVkxOW1XNldKTTVoSkF6d3FFdzFNTW5QTWQwX28yM0Uyd1cway1NUE55bmR6TGxmU2c5MmRBRzJsYzNrX2Q2ZzVPbThTbUdPOHpjUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) - Regulatory Tailwind Meets Operational Reset: A Mispriced Recovery", "summary": "This article analyzes biote Corp. (BTMD), a hormone optimization company, highlighting its potential for recovery driven by regulatory changes and operational improvements. The removal of the FDA black box warning for compounded testosterone products is seen as a key catalyst, ex", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-btmd/biote/tcnvoeog-biote-corp-btmd-regulatory-tailwind-meets-operational-reset-a-mispriced-recovery", "source_name": "Simply Wall Street", "published_at": "2026-05-24T20:38:48", "published_display": "24 May 2026 20:38", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. (BTMD) Extends Decline: Down 3.86% as Support Level Comes into Focus - Narrow Range Breakout", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNUGVzMzZ0TjVrNFRhR0pPUlRuRHk5X05LWG91Qi1oZ1BLUTNWZ2JZS3JDZGVCaUpNb2xmR0l2N3ZmT0xvMTE2S1pvNnZmM1ByNmg2cFN6TGRPdXl6T043b1RlRDNLMHJhUl9hTWJleFFLTUlidXBXQnpRb2plaW5URDlYM3N1djRha2R1OWQ0bHlyeVRQNnZMZVdYakw3d2FPdS16amx2RWs2eEU2eGFwZmFra1pWajAyYTNKYmViSHBpT1RJWWQ4?oc=5", "source_name": "B\u00f6l\u00fcm Sonu Canavar\u0131", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (NASDAQ: BTMD) investors back board nominees and Deloitte as 2026 auditor", "summary": "Biote Corp. shareholders have elected Andrew R. Heyer and Dana Jacoby as Class I directors to serve until the 2029 annual meeting. The stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 202", "url": "https://www.stocktitan.net/sec-filings/BTMD/8-k-biote-corp-reports-material-event-1666f22e6824.html", "source_name": "Stock Titan", "published_at": "2026-05-18T20:09:46", "published_display": "18 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dow Theory Letters - Biote Corp. - Class A common stock (Nasdaq:BTMD) Stock Quote", "summary": "This article provides a stock quote and recent news for Biote Corp. (Nasdaq: BTMD). It includes current trading information, financial performance data, and a list of press releases and earnings call transcripts from various sources. The stock was trading at $1.910, down 3.05% at", "url": "https://markets.financialcontent.com/dowtheoryletters/quote?Symbol=NQ%3ABTMD", "source_name": "FinancialContent", "published_at": "2026-05-15T15:08:52", "published_display": "15 May 2026 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) director Andrew Heyer receives options and 35,259 deferred RSUs", "summary": "biote Corp. director Andrew Heyer was granted equity-based compensation awards, including stock options for 130,000 shares of Class A Common Stock with an exercise price of $2.20 and 35,259 Deferred Settlement RSUs. The stock options will vest on the earlier of May 12, 2027, or t", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-c4c5483bdfab.html", "source_name": "Stock Titan", "published_at": "2026-05-14T20:38:58", "published_display": "14 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) grants options and RSUs to director", "summary": "Bioten Corp. (BTMD) director Stephen Mark Cone has been granted 130,000 stock options at an exercise price of $2.20 per share, vesting by May 2027. He also received 31,481 Deferred Settlement RSUs, which are immediately vested but deferred until his separation from service. These", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-ed0fbea05d71.html", "source_name": "Stock Titan", "published_at": "2026-05-14T14:39:18", "published_display": "14 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote (BTMD) director awarded 130,000 options and deferred RSUs", "summary": "Biote Corp. director Debra L. Morris reported compensation-related equity activity, including the exercise of derivative rights into 21,407 Class A Common Stock shares, bringing her direct holdings to 71,562 shares. She was also granted 130,000 stock options with a $2.20 exercise", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-a43471cb594a.html", "source_name": "Stock Titan", "published_at": "2026-05-13T22:09:19", "published_display": "13 May 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) director receives 195,000 stock options at $2.20 strike", "summary": "biote Corp. director Marc D. Beer was granted 195,000 stock options with an exercise price of $2.20 per share. These options will vest on May 12, 2027, or the day before the company's 2027 annual meeting, contingent on his continuous service. This transaction is a grant and not a", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-3d69c5917b68.html", "source_name": "Stock Titan", "published_at": "2026-05-13T22:09:19", "published_display": "13 May 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote (BTMD) director receives 130,000 options and 37,777 deferred RSUs", "summary": "biote Corp. director Dana Lynn Jacoby was granted 130,000 stock options with an exercise price of $2.20 per share, vesting by May 12, 2027. She also received 37,777 Deferred Settlement RSUs, which are fully vested but settle in calendar year 2027 or upon her separation from servi", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-79395e988954.html", "source_name": "Stock Titan", "published_at": "2026-05-13T22:09:19", "published_display": "13 May 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) director Barrera receives 121,452 stock options at $2.20", "summary": "Richard R. Barrera, a director and ten percent owner of biote Corp. (BTMD), was granted 121,452 stock options for Class A Common Stock with an exercise price of $2.20 per share. These options will vest on the earlier of May 12, 2027, or the day before the 2027 Annual Meeting of S", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-ba3f82b913a4.html", "source_name": "Stock Titan", "published_at": "2026-05-13T22:09:19", "published_display": "13 May 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bandera Partners reports 2.07M shares in biote Corp. (BTMD)", "summary": "Bandera Partners LLC has filed an Amendment No. 3 to a Schedule 13G/A, reporting a beneficial ownership of 2,065,482 shares of biote Corp.'s Class A common stock, representing a 6.4% stake. The shares are held by Bandera Master Fund L.P., with Bandera Partners acting as the inves", "url": "https://www.stocktitan.net/sec-filings/BTMD/schedule-13g-a-biote-corp-amended-passive-investment-disclosure-1503b9c56050.html", "source_name": "Stock Titan", "published_at": "2026-05-13T20:09:19", "published_display": "13 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/946518cb-eac2-39bc-9c89-893fac5cd04f/biote-corp.-q1-2026-earnings.html", "source_name": "Moby", "published_at": "2026-05-07T12:30:00+00:00", "published_display": "07 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Q1 2026 Earnings Call: Complete Transcript", "summary": "Biote reported an 8.3% revenue decline to $44.9 million in Q1 2026, primarily due to a 13.2% drop in procedure revenue caused by a voluntary product recall affecting hormone pellet supply. Despite this, dietary supplement revenue increased by 19.1%. The company maintains its 2026", "url": "https://www.sahmcapital.com/news/content/biote-q1-2026-earnings-call-complete-transcript-2026-05-07", "source_name": "Sahm", "published_at": "2026-05-07T11:09:53", "published_display": "07 May 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/5b36514e-fc70-3fba-8caa-e745643689ef/biote-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-06T23:35:21+00:00", "published_display": "06 May 2026 23:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote (BTMD) Q1 2026 Earnings Call Transcript", "summary": "", "url": "https://finance.yahoo.com/m/34c360e9-7346-3543-8a88-990621c097ea/biote-%28btmd%29-q1-2026-earnings.html", "source_name": "Motley Fool", "published_at": "2026-05-06T23:05:04+00:00", "published_display": "06 May 2026 23:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. (BTMD) Releases Q1 2026 Earnings: Revenue Falls 8.3% While EPS Beats Estimates", "summary": "Biote Corp. (BTMD) reported its Q1 2026 earnings, showing an 8.3% year-over-year decrease in revenue to $44.9 million and a 14.9% decline in gross profit to $31.0 million. Despite the revenue shortfall compared to estimates, diluted EPS of $0.06 surpassed the $0.05 expectation. T", "url": "https://www.quiverquant.com/news/Biote+Corp.+(BTMD)+Releases+Q1+2026+Earnings:+Revenue+Falls+8.3%25+While+EPS+Beats+Estimates", "source_name": "Quiver Quantitative", "published_at": "2026-05-06T22:40:48", "published_display": "06 May 2026 22:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) Q1 Earnings and Revenues Lag Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOQV9yVW5vNVhPNkVYZVV6dTQ4MVhUd3BBbWdsOGhTNHdCZTF1TF95eE5tbVhIenNFU3NURE9Ubk9paF9mQ0pjaHdKcmNfYmt2cl9pVU0tY29ydFFnV3ZpcDNpZXFPb1paa2otUHI1U2NLc001OWxLaW9WU2h4aXdWRmdLWnlVTVVGSUlucHFFYWFrQVlIcldCc3JGMGk?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote (BTMD) grants 88,800 stock options to General Counsel Monico", "summary": "biote Corp. (BTMD) has granted its General Counsel, Daniel Michael Monico, 88,800 employee stock options for Class A common stock at an exercise price of $2.19 per share. These options are part of Monico's compensation package and will vest in two stages: half on April 27, 2028, ", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-4f7a76b45f45.html", "source_name": "Stock Titan", "published_at": "2026-05-04T20:28:18", "published_display": "04 May 2026 20:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The biote (BTMD) Narrative Is Shifting As Targets Tighten And Guidance Holds", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxONTNLTzVaRnNyTXhLVGpRNkNEcDg4cmJNVmxybmRkbW12Wkhxelh1MXM1MXFQTnBzc3VSN3V3eHFFVE1UQldFY3V4X29OTEdNWGZlY1NVTzM1S0RiMFdtRkc1NXlFQWZnSDFkTUEyT3FQbnlkQXUydnpNNXctcEdWcnpHTTZFZFlLYkpOeHNaM2c3QnNxNVo3b2FjQ2NfczBPS3R1Wk5GcG9wUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Lawsuit 2026: Claims, Risks & How to File", "summary": "Biote Medical faces legal action in 2026 over its hormone pellet therapy, with patients alleging harm and misleading marketing regarding its safety and risks. The lawsuits, which include claims of negligence, product liability, and consumer fraud, center on complications like car", "url": "https://lawfold.com/biote-lawsuit/", "source_name": "lawfold.com", "published_at": "2026-04-13T09:40:13", "published_display": "13 Apr 2026 09:40", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Investment Story For Biote (BTMD) Is Shifting With Reset Expectations And 2026 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQRENNN042WlY1bGttdUxmSGRSTXNtR25TYTZHWUdwR0d5YkdDUkNjQU9lTU5kUVdBenQ2dnpOUGJGUGxCRmFaNjBPUVJSS3dPRnR0M3lXbjFmOVJYWmIyREl1N2d1RFQteF9HTlNiZU4wUEZabmRzZ1VLejZXT3hfd1RfdUd6aVhYUjhpSVJWTUJlb3ZIS3FrRExpS0lsV2ZhQjBB?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote (NASDAQ: BTMD) highlights 2025 revenue and 2026 guidance", "summary": "Biote (NASDAQ: BTMD) has released an updated investor presentation detailing its 2025 performance and 2026 outlook. For 2025, the company reported revenues of $192.2 million and Adjusted EBITDA of $53.5 million. Looking ahead to 2026, Biote expects revenue to exceed $190 million ", "url": "https://www.stocktitan.net/sec-filings/BTMD/8-k-biote-corp-reports-material-event-2e7de28310fc.html", "source_name": "Stock Titan", "published_at": "2026-04-03T21:39:16", "published_display": "03 Apr 2026 21:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote posts April 2026 investor presentation highlighting $192.2M 2025 revenue and $53.5M Adj. EBITDA", "summary": "Biote has released its April 2026 investor presentation, detailing its 2025 financial performance with $192.2 million in revenue and $53.5 million in adjusted EBITDA. The company also reported having over 9,200 certified practitioners and nearly 400,000 active patients by the end", "url": "https://www.tradingview.com/news/tradingview:6bc20463c6036:0-biote-posts-april-2026-investor-presentation-highlighting-192-2m-2025-revenue-and-53-5m-adj-ebitda/", "source_name": "TradingView", "published_at": "2026-04-03T20:41:31", "published_display": "03 Apr 2026 20:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) CFO receives 107,169 employee stock options at $1.43", "summary": "biote Corp.'s Chief Financial Officer, Robert Charles Peterson, was granted 107,169 employee stock options for Class A Common Stock with an exercise price of $1.43 per share. These options expire on March 31, 2036, and vest over time, with 25% vesting on April 1, 2027, and the re", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-b4185bd750e1.html", "source_name": "Stock Titan", "published_at": "2026-04-03T17:39:50", "published_display": "03 Apr 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) CEO awarded 441,653 stock options at $1.43 strike price", "summary": "biote Corp.'s CEO, Bret Christensen, has been granted 441,653 employee stock options with a strike price of $1.43 per share. These options are part of his compensation, with 25% vesting on April 1, 2027, and the remainder vesting in 36 monthly installments thereafter, contingent ", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-c1d138be1fe7.html", "source_name": "Stock Titan", "published_at": "2026-04-03T17:39:50", "published_display": "03 Apr 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote (BTMD) details 2026 virtual meeting, board elections and pay", "summary": "Biote Corp. (BTMD) has announced its 2026 annual virtual stockholder meeting for May 12, 2026, where shareholders will vote on electing two Class I directors and ratifying Deloitte & Touche LLP as its independent auditor. The proxy statement also provided details on board composi", "url": "https://www.stocktitan.net/sec-filings/BTMD/def-14a-biote-corp-definitive-proxy-statement-96a7973f5e7f.html", "source_name": "Stock Titan", "published_at": "2026-04-02T20:19:39", "published_display": "02 Apr 2026 20:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote (BTMD) Balance Sheet & Financial Health Metrics", "summary": "This article provides an overview of biote (BTMD)'s financial health and balance sheet metrics. It highlights key figures such as a negative shareholder equity of $-50.4M and total debt of $107.0M, resulting in a debt-to-equity ratio of -212.4%. The company's EBIT is $35.1M, with", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-btmd/biote/health", "source_name": "Simply Wall Street", "published_at": "2026-03-27T18:09:50", "published_display": "27 Mar 2026 18:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. Stock Plummets to New 52-Week Low of $1.68", "summary": "biote Corp., a microcap hospital industry company, has reached a new 52-week low of $1.68, experiencing a 73.6% stock price decline over the past year. The company is facing significant financial difficulties, including a negative book value, poor debt management, and decreased n", "url": "https://www.marketsmojo.com/news/stocks-in-action/biote-corp-stock-plummets-to-new-52-week-low-of-168-3885511", "source_name": "Markets Mojo", "published_at": "2026-03-21T06:38:56", "published_display": "21 Mar 2026 06:38", "sentiment": "negative", "sentiment_pct": 13, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. Q4 2025 Earnings Call Insights", "summary": "Biote Corp. reported a significant expansion of its sales team to over 90 members by the end of 2025 and highlighted a Q4 2025 revenue of $46.4 million, with dietary supplement revenue growing 16% to $11.7 million despite a 13% decline in procedure revenue. The company forecasts ", "url": "https://intellectia.ai/news/stock/biote-corp-q4-2025-earnings-call-insights", "source_name": "Intellectia AI", "published_at": "2026-03-14T20:51:29", "published_display": "14 Mar 2026 20:51", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Biote Corp misses Q4 2025 earnings expectations", "summary": "Biote Corp reported missing its Q4 2025 earnings and revenue forecasts, with an EPS of $0.06 against an expected $0.09 and revenue of $46.4 million versus $47.12 million. Despite the misses and a year-over-year revenue decline of 6.9%, the company's stock remained stable in after", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-biote-corp-misses-q4-2025-earnings-expectations-93CH-4555872", "source_name": "Investing.com", "published_at": "2026-03-14T18:39:25", "published_display": "14 Mar 2026 18:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. Earnings Call Maps Pain Now, Promise Later", "summary": "Biote Corp.'s Q4 earnings call revealed a mixed performance, with operational gains in dietary supplements and cost controls offsetting declines in its core procedure business due to clinic attrition and a product recall. Despite a drop in revenue and adjusted EBITDA in Q4 2025, ", "url": "https://www.tipranks.com/news/company-announcements/biote-corp-earnings-call-maps-pain-now-promise-later", "source_name": "TipRanks", "published_at": "2026-03-13T13:39:55", "published_display": "13 Mar 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. subsidiary Asteria Health initiates voluntary recall of hormone pellets", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPMF84VjcwNk5FcEhlcnNNNFQzQXZBMm5JWS02TGNZTG5xengxTEh3b1RlN0psamVmZXppT295TjhscXltUU5pOXhnZXNteE5BeWU5OEdFZFUtNUhMUEpuNkNuMEU2Ym9nblFKNWg4aTdMWTMxMXpmNWg2WFEzYlN1N2pyZk4yS0ZhZUx0bFQ1OHlVTVk3YXB4bVNzemdNTG5JZDV2bGk3ZEZqSW5jUU8wYTMtYXdqMjl0cFVpemxtZ3BaZTh5cTNQclFaR1doTjhHYjVLMg?oc=5", "source_name": "Investing.com", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp.'s (NASDAQ:BTMD) latest 10% decline adds to one-year losses, institutional investors may consider drastic measures", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-17T08:00:00+00:00", "published_display": "17 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Restructuring At Biote Will Drive Greater Growth And Profitability (NASDAQ:BTMD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxONEVUekVMY0w2eFVsemJqNGEzdTZEaVhaS2lnNmt3b3ZYUjRHRjA5UXFTaHh6NHc1Y0NCSC1SNndkdzNIMWN6aWtyZFNkWFBUTU5vcXltbHY2aklWRWFXMzF3QnpUb241YkN0NEQ2NUNmcThFX2VpakFTUElnWEluRlRrTjktQ1F0emk2RlFYVlJVem1mQ0hMOWVZSk9UTm9OQkRJbW5WeURaSUU?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-09-10T07:00:00+00:00", "published_display": "10 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. SEC 10-K Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNNXpqRmItblhWTElUa0VCSXRXVU1zSlVPZGU2M0FRWE4xUmZ0Q1RRV1VVM1Q2TGlVdDliVlV4X3VtXy1QYnoyMkNKaXg5dkVkYWZubm5DcGd6bEc1MWtxdnJmQkFQSmZZcG5DcGNrZFVkRHB0a3BVTUl5d0h6MFU0TWtPbkFiU3ZsMXhNdWpBQ21Odw?oc=5", "source_name": "TradingView", "published_at": "2025-03-14T07:00:00+00:00", "published_display": "14 Mar 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote settles founder's lawsuit by buying back his nearly $77 million in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNX3JzVFViMEU5SGxrM2lLVmhqbUNJLXp6ME5vSWt3YlVNdU5FS29sNDZiWlcwYU9neHhDby1za1dRNHQ4UmJMZjNQX2ZlUm1qTXhhX0FjbHRDaTMxOERxV3J4R3pURjlma0VCa0hpMlFka0plQV9INzJuczctOTFhRzRBUGRvUTZPU3U0VUFpVV84SUU4eThIT2lBZUl4YkI2bXBnZEZCSTJYeXNMZk9HMFRZeWFzT2J3bnlZX1RSMXhXcTM5eXZoZTFxeFhTMHZ5d1E?oc=5", "source_name": "Dallas News", "published_at": "2024-02-21T08:00:00+00:00", "published_display": "21 Feb 2024 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote to be Listed on Nasdaq through a Business Combination with Haymaker Acquisition Corp. III", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQYW81QldwRGhILUZVZWxjRUJ0ek9ZRnhsRXZGNGVkbGlVb2ctSTJDYnktcTA4TjJmOUhYOUx4bDgtMW8xQU8wZFdsM19uaDFNVkJzNURQOS10TFJLYjB5LWVwMkRaam5xZV85c3JydmVLRkJGaU5yTEMtRHFINnVUX24tUzRNVGk4ek1vNTlxMG5BZXJjOFNKeVd5MjZrQ2hvMVlNZkg1dWxrckFkOGY4VUxrN2FaUzA?oc=5", "source_name": "IPO Edge", "published_at": "2021-12-13T13:30:03+00:00", "published_display": "13 Dec 2021 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to earnings forward of Biote Corp. \u2013 NASDAQ:BTMD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPVVZCQWE1UWhmVXA1aHRjYUJfOU9aSW9HSFk2bUtCTUVOZGk4a0s0bmN3blE3ZUFraTYzVy1ZV3JUX2x1bFU0TVlKUjFxMFNoRjU4QWppU21XczVuLVZEeHpVemZDWkkzVTJSc2lnMU9tSjFVTHlvRFVjZzF5NGRxdllKSVpQcFA1Zk84S3NTUC11Y0wwUUVVZmZqSExBcHNmclE?oc=5", "source_name": "TradingView", "published_at": "2026-07-06T00:37:48+00:00", "published_display": "06 Jul 2026 00:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. (BTMD) Climbs 9% as Stock Rebounds From Support Level - Early Entry Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPSHhMYlRpTnlfZUpHX1JUcmtxYV9KMmNkbkN1NXpyaTg4Wk5iUGdnQ2wxSDlxWlIxYUU5eDl6SXFxRjdQM1dlRXN0VEVIeUt0bzZuMmx6cXdxRm9va2JzZXczZTZvQnNjc2tpR0VWRDlqMExQeU9Zblc4RHB4U1d1SE1CMjRKX0FOOUVINXNWLU9NYU5SOEVacG00UTVYQWNhMlZDQjM3MV9ZdjJ6?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. (BTMD) Climbs 9% as Stock Rebounds From Support Level - Thematic ETF Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOeGFHeWtQdTExWWtTaVQ0VlBNSVZrN3M5MWxXUURJWnNJb1FuU19MdGptcmMtMGtNVzJuUFBHdnVfeGc2ZUxtTzh5Z1pKZXZkUzdDTnBSX0w3UThZaHhYTEN4Z2cwdEt1X2FKUWREcnpqVU5PLWsxSHRiWm1BNWpQNzIwcHYwYlA0RE9wVDQyN3N4dEVnVzQ3Nm83WFVKQ0U4LTdWdjZR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp.(NasdaqGM: BTMD) dropped from Russell 2500 Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSDhfODViMTlfSmFRMzlCU3dQLW1GS2lBQXdPcWlvMEVubnVwSjlBc01ESlBNc25WdDg3Q0lUM3cwTF83TXRYbUhDdzJlQzl0TzBVd2ZNNUFHemFSNTZIR18wSjN2QU9PTm5zTXZUYTk1S2Uwb05OX1FxaTdxRlI0U2QtQktTaHpuXzJJc0FmQTdnZWkwRFFHLUd2dnFVSUZqRnhFTjUwT0VXTjJTeVVRT3hSd0RhTUs4Z3ZN?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp.(NasdaqGM: BTMD) dropped from Russell 3000E Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPdnRGZUYwaV9mUEJtUkZoc0xOa3VOTl9makNOWW9tN2U5UWdXYnhsOC1XczhjYndBN0s3a042ZXlJck5nQklIeXQzVy0tSlJoajFIWTVXUGZSbEFHcThoRFNlYUpiQVc3TGhuZTJtc01qNEtjNW56VmJvNU1IMllYckVCekVmT2tkUW9uVjV6dm9fZ0FMRDJ4T3BEVTJaZkhpclFRVlFXQ3pXU0F4R2Rr?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp.(NasdaqGM: BTMD) dropped from Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOVUdCdHdTSm5kMXpXSUd3NEpfNV9WZjNsU3NjZmRqdVRZRU9PQTZ3YkNLQXNqQ1N3aFJuYmxUc25DSkw5LTR2SGNOTnc1ay14bXJMMTZHMFJwRUxJbHhFby1WczA0cS1tSE1SbDZOYXRocTZXaGZHZzkyNlNnTzg5WFNwMjdINDdJWWVMMFhJOHZERk1wYnlsZlFuUmowaEEweXdTNXR0M1prRDBtaTF6RnNKelkwTjBlbEJfTQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. Class A Actuals & Estimates (NASDAQ:BTMD)", "summary": "This article provides an overview of Biote Corp. (NASDAQ: BTMD) stock, including its current price, historical performance, analyst forecasts, volatility, market capitalization, and financial results. It details recent earnings and revenue, upcoming earnings dates, and confirms t", "url": "https://www.tradingview.com/symbols/NASDAQ-BTMD/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T06:41:16", "published_display": "26 Jun 2026 06:41", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. (BTMD) Holds Steady Near Support as Slight Decline Persists - IV Contraction", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNZzFCdWNrdWs3d3pvVm40ellVb2pXUm1GTEU3czM3ZGw1a1VVaGc4Q3owN0w2VG5TTWJyVjNidUlKQmlTdEZzWktLSTJMVTJ1bjdJcmVuVHZLNDBIMlJ0VEJCVGxXekZTaDRoV2xFTU5jTTBfTld2YUdiUERvMEZPUVlRaDRnYTJHTFNuVjhqZkNrLXVrQ0k3b1Q4cXUxNWstcTdZWXBVT2E5azJIMTQ3cXpn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) interim CEO receives 206,746 stock options at $2.46 strike", "summary": "biote Corp.'s interim CEO, Robert Charles Peterson, was granted 206,746 stock options with an exercise price of $2.46 per share, set to expire on June 11, 2036. The options will vest over time, with 25% vesting on June 12, 2027, and the remainder vesting in 36 equal monthly insta", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-a123b6448486.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:09:47", "published_display": "16 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. (BTMD) Slides 2.67% as Stock Tests Key Support Levels - Smart Beta Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQVGlnOUdCNWhsNDBFc1hidVlFVDVJTWpxd3JUVGMtU2EyWDBhenFxOFJReVYzcHpYTGRNa2dFNFRpUFU1R01JdmlHVE9UUVlSM3Q2ck1vemNJMXNfWG1yNGRFaHphU1hDOU5tZTJod0haWXVQa0h1SnJkOEFXNG83aElmX1J2WDRlMExEVGNRNUg3U2VPWngyXzNnLTdPSmpoRkdvRw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) director receives 130,000 stock options at $2.34 strike", "summary": "biote Corp. director Bret Christensen was granted 130,000 stock options with an exercise price of $2.34 per share, expiring on June 7, 2036. These options will vest on the earlier of June 8, 2027, or the day before the company's 2027 Annual Meeting, provided Christensen remains i", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-d3bcbfa18a04.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:10:31", "published_display": "10 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) Executive Chairman receives 114,157 stock options at $2.34", "summary": "biote Corp.'s Executive Chairman, Marc D. Beer, was granted 114,157 employee stock options with an exercise price of $2.34 per share, expiring on June 7, 2036. These options will vest over time, with 25% vesting on June 8, 2027, and the remaining 75% vesting in 36 equal monthly i", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-be47adcb08fa.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:10:31", "published_display": "10 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Evolving Story For biote (BTMD) May Shape Future Investor Expectations", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/evolving-story-biote-btmd-may-080607062.html", "source_name": "Simply Wall St.", "published_at": "2026-06-06T08:06:07+00:00", "published_display": "06 Jun 2026 08:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Announces Interim CEO Amid Leadership Transition Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPbUdaQnBLSUQ1OHZWcHZKZkxRLWNmYWdhWGZiTXlmX3FJQWdtcEdhczg2a3pmR3A5OE5QSzNzYmc5eHVYVWFVazZsYXdUN1ozY01TQVB6VUpDb1ZBWXVva19qY3k3ajlZXzBKQ18tMVFQZUZITFR6bU1fUFBjTW1WSXZ1S0JQNnhLeUpqNV9wNDZ6ZkhUX2pMZmdBRV9KcjFiTGdGUDZtb1JaU09hVnpMandXZ3d4MzlJZGttVFZnSXZ5Si1HZEVhRmE1SVhYZ1Z4UlJCRE1GaWs?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote (NASDAQ: BTMD) names interim CEO, appoints Executive Chairman and reaffirms 2026 outlook", "summary": "Biote (NASDAQ: BTMD) announced a leadership transition, naming Robert Peterson as Interim CEO and Marc Beer as Executive Chairman, following Bret Christensen's resignation for personal reasons. The company reaffirmed its full-year 2026 guidance, expecting revenue above $190 milli", "url": "https://www.stocktitan.net/sec-filings/BTMD/8-k-biote-corp-reports-material-event-07698fab733b.html", "source_name": "Stock Titan", "published_at": "2026-06-02T23:10:45", "published_display": "02 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/biote-appoints-komal-bajaj-md-120000439.html", "source_name": "Business Wire", "published_at": "2026-06-01T12:00:00+00:00", "published_display": "01 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NYC hospital quality chief Komal Bajaj becomes Biote CMO", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQWVQ4cmJDUzdnbHVEc2VjaXh0ZVJPUVRTWm05Yjl3UWlLYmgySEFkTDZ2MFFSaHZuRUxGMmhxTkYxcDdscnpRUlBicTcxYUVKa3ZFeC15Z0tWMFlxTVkxOW1XNldKTTVoSkF6d3FFdzFNTW5QTWQwX28yM0Uyd1cway1NUE55bmR6TGxmU2c5MmRBRzJsYzNrX2Q2ZzVPbThTbUdPOHpjUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) - Regulatory Tailwind Meets Operational Reset: A Mispriced Recovery", "summary": "This article analyzes biote Corp. (BTMD), a hormone optimization company, highlighting its potential for recovery driven by regulatory changes and operational improvements. The removal of the FDA black box warning for compounded testosterone products is seen as a key catalyst, ex", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-btmd/biote/tcnvoeog-biote-corp-btmd-regulatory-tailwind-meets-operational-reset-a-mispriced-recovery", "source_name": "Simply Wall Street", "published_at": "2026-05-24T20:38:48", "published_display": "24 May 2026 20:38", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. (BTMD) Extends Decline: Down 3.86% as Support Level Comes into Focus - Narrow Range Breakout", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNUGVzMzZ0TjVrNFRhR0pPUlRuRHk5X05LWG91Qi1oZ1BLUTNWZ2JZS3JDZGVCaUpNb2xmR0l2N3ZmT0xvMTE2S1pvNnZmM1ByNmg2cFN6TGRPdXl6T043b1RlRDNLMHJhUl9hTWJleFFLTUlidXBXQnpRb2plaW5URDlYM3N1djRha2R1OWQ0bHlyeVRQNnZMZVdYakw3d2FPdS16amx2RWs2eEU2eGFwZmFra1pWajAyYTNKYmViSHBpT1RJWWQ4?oc=5", "source_name": "B\u00f6l\u00fcm Sonu Canavar\u0131", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (NASDAQ: BTMD) investors back board nominees and Deloitte as 2026 auditor", "summary": "Biote Corp. shareholders have elected Andrew R. Heyer and Dana Jacoby as Class I directors to serve until the 2029 annual meeting. The stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 202", "url": "https://www.stocktitan.net/sec-filings/BTMD/8-k-biote-corp-reports-material-event-1666f22e6824.html", "source_name": "Stock Titan", "published_at": "2026-05-18T20:09:46", "published_display": "18 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dow Theory Letters - Biote Corp. - Class A common stock (Nasdaq:BTMD) Stock Quote", "summary": "This article provides a stock quote and recent news for Biote Corp. (Nasdaq: BTMD). It includes current trading information, financial performance data, and a list of press releases and earnings call transcripts from various sources. The stock was trading at $1.910, down 3.05% at", "url": "https://markets.financialcontent.com/dowtheoryletters/quote?Symbol=NQ%3ABTMD", "source_name": "FinancialContent", "published_at": "2026-05-15T15:08:52", "published_display": "15 May 2026 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) director Andrew Heyer receives options and 35,259 deferred RSUs", "summary": "biote Corp. director Andrew Heyer was granted equity-based compensation awards, including stock options for 130,000 shares of Class A Common Stock with an exercise price of $2.20 and 35,259 Deferred Settlement RSUs. The stock options will vest on the earlier of May 12, 2027, or t", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-c4c5483bdfab.html", "source_name": "Stock Titan", "published_at": "2026-05-14T20:38:58", "published_display": "14 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) grants options and RSUs to director", "summary": "Bioten Corp. (BTMD) director Stephen Mark Cone has been granted 130,000 stock options at an exercise price of $2.20 per share, vesting by May 2027. He also received 31,481 Deferred Settlement RSUs, which are immediately vested but deferred until his separation from service. These", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-ed0fbea05d71.html", "source_name": "Stock Titan", "published_at": "2026-05-14T14:39:18", "published_display": "14 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote (BTMD) director awarded 130,000 options and deferred RSUs", "summary": "Biote Corp. director Debra L. Morris reported compensation-related equity activity, including the exercise of derivative rights into 21,407 Class A Common Stock shares, bringing her direct holdings to 71,562 shares. She was also granted 130,000 stock options with a $2.20 exercise", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-a43471cb594a.html", "source_name": "Stock Titan", "published_at": "2026-05-13T22:09:19", "published_display": "13 May 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) director receives 195,000 stock options at $2.20 strike", "summary": "biote Corp. director Marc D. Beer was granted 195,000 stock options with an exercise price of $2.20 per share. These options will vest on May 12, 2027, or the day before the company's 2027 annual meeting, contingent on his continuous service. This transaction is a grant and not a", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-3d69c5917b68.html", "source_name": "Stock Titan", "published_at": "2026-05-13T22:09:19", "published_display": "13 May 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote (BTMD) director receives 130,000 options and 37,777 deferred RSUs", "summary": "biote Corp. director Dana Lynn Jacoby was granted 130,000 stock options with an exercise price of $2.20 per share, vesting by May 12, 2027. She also received 37,777 Deferred Settlement RSUs, which are fully vested but settle in calendar year 2027 or upon her separation from servi", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-79395e988954.html", "source_name": "Stock Titan", "published_at": "2026-05-13T22:09:19", "published_display": "13 May 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) director Barrera receives 121,452 stock options at $2.20", "summary": "Richard R. Barrera, a director and ten percent owner of biote Corp. (BTMD), was granted 121,452 stock options for Class A Common Stock with an exercise price of $2.20 per share. These options will vest on the earlier of May 12, 2027, or the day before the 2027 Annual Meeting of S", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-ba3f82b913a4.html", "source_name": "Stock Titan", "published_at": "2026-05-13T22:09:19", "published_display": "13 May 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bandera Partners reports 2.07M shares in biote Corp. (BTMD)", "summary": "Bandera Partners LLC has filed an Amendment No. 3 to a Schedule 13G/A, reporting a beneficial ownership of 2,065,482 shares of biote Corp.'s Class A common stock, representing a 6.4% stake. The shares are held by Bandera Master Fund L.P., with Bandera Partners acting as the inves", "url": "https://www.stocktitan.net/sec-filings/BTMD/schedule-13g-a-biote-corp-amended-passive-investment-disclosure-1503b9c56050.html", "source_name": "Stock Titan", "published_at": "2026-05-13T20:09:19", "published_display": "13 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/946518cb-eac2-39bc-9c89-893fac5cd04f/biote-corp.-q1-2026-earnings.html", "source_name": "Moby", "published_at": "2026-05-07T12:30:00+00:00", "published_display": "07 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Q1 2026 Earnings Call: Complete Transcript", "summary": "Biote reported an 8.3% revenue decline to $44.9 million in Q1 2026, primarily due to a 13.2% drop in procedure revenue caused by a voluntary product recall affecting hormone pellet supply. Despite this, dietary supplement revenue increased by 19.1%. The company maintains its 2026", "url": "https://www.sahmcapital.com/news/content/biote-q1-2026-earnings-call-complete-transcript-2026-05-07", "source_name": "Sahm", "published_at": "2026-05-07T11:09:53", "published_display": "07 May 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/5b36514e-fc70-3fba-8caa-e745643689ef/biote-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-06T23:35:21+00:00", "published_display": "06 May 2026 23:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote (BTMD) Q1 2026 Earnings Call Transcript", "summary": "", "url": "https://finance.yahoo.com/m/34c360e9-7346-3543-8a88-990621c097ea/biote-%28btmd%29-q1-2026-earnings.html", "source_name": "Motley Fool", "published_at": "2026-05-06T23:05:04+00:00", "published_display": "06 May 2026 23:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. (BTMD) Releases Q1 2026 Earnings: Revenue Falls 8.3% While EPS Beats Estimates", "summary": "Biote Corp. (BTMD) reported its Q1 2026 earnings, showing an 8.3% year-over-year decrease in revenue to $44.9 million and a 14.9% decline in gross profit to $31.0 million. Despite the revenue shortfall compared to estimates, diluted EPS of $0.06 surpassed the $0.05 expectation. T", "url": "https://www.quiverquant.com/news/Biote+Corp.+(BTMD)+Releases+Q1+2026+Earnings:+Revenue+Falls+8.3%25+While+EPS+Beats+Estimates", "source_name": "Quiver Quantitative", "published_at": "2026-05-06T22:40:48", "published_display": "06 May 2026 22:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) Q1 Earnings and Revenues Lag Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOQV9yVW5vNVhPNkVYZVV6dTQ4MVhUd3BBbWdsOGhTNHdCZTF1TF95eE5tbVhIenNFU3NURE9Ubk9paF9mQ0pjaHdKcmNfYmt2cl9pVU0tY29ydFFnV3ZpcDNpZXFPb1paa2otUHI1U2NLc001OWxLaW9WU2h4aXdWRmdLWnlVTVVGSUlucHFFYWFrQVlIcldCc3JGMGk?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote (BTMD) grants 88,800 stock options to General Counsel Monico", "summary": "biote Corp. (BTMD) has granted its General Counsel, Daniel Michael Monico, 88,800 employee stock options for Class A common stock at an exercise price of $2.19 per share. These options are part of Monico's compensation package and will vest in two stages: half on April 27, 2028, ", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-4f7a76b45f45.html", "source_name": "Stock Titan", "published_at": "2026-05-04T20:28:18", "published_display": "04 May 2026 20:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The biote (BTMD) Narrative Is Shifting As Targets Tighten And Guidance Holds", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxONTNLTzVaRnNyTXhLVGpRNkNEcDg4cmJNVmxybmRkbW12Wkhxelh1MXM1MXFQTnBzc3VSN3V3eHFFVE1UQldFY3V4X29OTEdNWGZlY1NVTzM1S0RiMFdtRkc1NXlFQWZnSDFkTUEyT3FQbnlkQXUydnpNNXctcEdWcnpHTTZFZFlLYkpOeHNaM2c3QnNxNVo3b2FjQ2NfczBPS3R1Wk5GcG9wUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Lawsuit 2026: Claims, Risks & How to File", "summary": "Biote Medical faces legal action in 2026 over its hormone pellet therapy, with patients alleging harm and misleading marketing regarding its safety and risks. The lawsuits, which include claims of negligence, product liability, and consumer fraud, center on complications like car", "url": "https://lawfold.com/biote-lawsuit/", "source_name": "lawfold.com", "published_at": "2026-04-13T09:40:13", "published_display": "13 Apr 2026 09:40", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Investment Story For Biote (BTMD) Is Shifting With Reset Expectations And 2026 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQRENNN042WlY1bGttdUxmSGRSTXNtR25TYTZHWUdwR0d5YkdDUkNjQU9lTU5kUVdBenQ2dnpOUGJGUGxCRmFaNjBPUVJSS3dPRnR0M3lXbjFmOVJYWmIyREl1N2d1RFQteF9HTlNiZU4wUEZabmRzZ1VLejZXT3hfd1RfdUd6aVhYUjhpSVJWTUJlb3ZIS3FrRExpS0lsV2ZhQjBB?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote (NASDAQ: BTMD) highlights 2025 revenue and 2026 guidance", "summary": "Biote (NASDAQ: BTMD) has released an updated investor presentation detailing its 2025 performance and 2026 outlook. For 2025, the company reported revenues of $192.2 million and Adjusted EBITDA of $53.5 million. Looking ahead to 2026, Biote expects revenue to exceed $190 million ", "url": "https://www.stocktitan.net/sec-filings/BTMD/8-k-biote-corp-reports-material-event-2e7de28310fc.html", "source_name": "Stock Titan", "published_at": "2026-04-03T21:39:16", "published_display": "03 Apr 2026 21:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote posts April 2026 investor presentation highlighting $192.2M 2025 revenue and $53.5M Adj. EBITDA", "summary": "Biote has released its April 2026 investor presentation, detailing its 2025 financial performance with $192.2 million in revenue and $53.5 million in adjusted EBITDA. The company also reported having over 9,200 certified practitioners and nearly 400,000 active patients by the end", "url": "https://www.tradingview.com/news/tradingview:6bc20463c6036:0-biote-posts-april-2026-investor-presentation-highlighting-192-2m-2025-revenue-and-53-5m-adj-ebitda/", "source_name": "TradingView", "published_at": "2026-04-03T20:41:31", "published_display": "03 Apr 2026 20:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) CFO receives 107,169 employee stock options at $1.43", "summary": "biote Corp.'s Chief Financial Officer, Robert Charles Peterson, was granted 107,169 employee stock options for Class A Common Stock with an exercise price of $1.43 per share. These options expire on March 31, 2036, and vest over time, with 25% vesting on April 1, 2027, and the re", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-b4185bd750e1.html", "source_name": "Stock Titan", "published_at": "2026-04-03T17:39:50", "published_display": "03 Apr 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. (BTMD) CEO awarded 441,653 stock options at $1.43 strike price", "summary": "biote Corp.'s CEO, Bret Christensen, has been granted 441,653 employee stock options with a strike price of $1.43 per share. These options are part of his compensation, with 25% vesting on April 1, 2027, and the remainder vesting in 36 monthly installments thereafter, contingent ", "url": "https://www.stocktitan.net/sec-filings/BTMD/form-4-biote-corp-insider-trading-activity-c1d138be1fe7.html", "source_name": "Stock Titan", "published_at": "2026-04-03T17:39:50", "published_display": "03 Apr 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote (BTMD) details 2026 virtual meeting, board elections and pay", "summary": "Biote Corp. (BTMD) has announced its 2026 annual virtual stockholder meeting for May 12, 2026, where shareholders will vote on electing two Class I directors and ratifying Deloitte & Touche LLP as its independent auditor. The proxy statement also provided details on board composi", "url": "https://www.stocktitan.net/sec-filings/BTMD/def-14a-biote-corp-definitive-proxy-statement-96a7973f5e7f.html", "source_name": "Stock Titan", "published_at": "2026-04-02T20:19:39", "published_display": "02 Apr 2026 20:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote (BTMD) Balance Sheet & Financial Health Metrics", "summary": "This article provides an overview of biote (BTMD)'s financial health and balance sheet metrics. It highlights key figures such as a negative shareholder equity of $-50.4M and total debt of $107.0M, resulting in a debt-to-equity ratio of -212.4%. The company's EBIT is $35.1M, with", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-btmd/biote/health", "source_name": "Simply Wall Street", "published_at": "2026-03-27T18:09:50", "published_display": "27 Mar 2026 18:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. Stock Plummets to New 52-Week Low of $1.68", "summary": "biote Corp., a microcap hospital industry company, has reached a new 52-week low of $1.68, experiencing a 73.6% stock price decline over the past year. The company is facing significant financial difficulties, including a negative book value, poor debt management, and decreased n", "url": "https://www.marketsmojo.com/news/stocks-in-action/biote-corp-stock-plummets-to-new-52-week-low-of-168-3885511", "source_name": "Markets Mojo", "published_at": "2026-03-21T06:38:56", "published_display": "21 Mar 2026 06:38", "sentiment": "negative", "sentiment_pct": 13, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. Q4 2025 Earnings Call Insights", "summary": "Biote Corp. reported a significant expansion of its sales team to over 90 members by the end of 2025 and highlighted a Q4 2025 revenue of $46.4 million, with dietary supplement revenue growing 16% to $11.7 million despite a 13% decline in procedure revenue. The company forecasts ", "url": "https://intellectia.ai/news/stock/biote-corp-q4-2025-earnings-call-insights", "source_name": "Intellectia AI", "published_at": "2026-03-14T20:51:29", "published_display": "14 Mar 2026 20:51", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Biote Corp misses Q4 2025 earnings expectations", "summary": "Biote Corp reported missing its Q4 2025 earnings and revenue forecasts, with an EPS of $0.06 against an expected $0.09 and revenue of $46.4 million versus $47.12 million. Despite the misses and a year-over-year revenue decline of 6.9%, the company's stock remained stable in after", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-biote-corp-misses-q4-2025-earnings-expectations-93CH-4555872", "source_name": "Investing.com", "published_at": "2026-03-14T18:39:25", "published_display": "14 Mar 2026 18:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. Earnings Call Maps Pain Now, Promise Later", "summary": "Biote Corp.'s Q4 earnings call revealed a mixed performance, with operational gains in dietary supplements and cost controls offsetting declines in its core procedure business due to clinic attrition and a product recall. Despite a drop in revenue and adjusted EBITDA in Q4 2025, ", "url": "https://www.tipranks.com/news/company-announcements/biote-corp-earnings-call-maps-pain-now-promise-later", "source_name": "TipRanks", "published_at": "2026-03-13T13:39:55", "published_display": "13 Mar 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote Corp. subsidiary Asteria Health initiates voluntary recall of hormone pellets", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPMF84VjcwNk5FcEhlcnNNNFQzQXZBMm5JWS02TGNZTG5xengxTEh3b1RlN0psamVmZXppT295TjhscXltUU5pOXhnZXNteE5BeWU5OEdFZFUtNUhMUEpuNkNuMEU2Ym9nblFKNWg4aTdMWTMxMXpmNWg2WFEzYlN1N2pyZk4yS0ZhZUx0bFQ1OHlVTVk3YXB4bVNzemdNTG5JZDV2bGk3ZEZqSW5jUU8wYTMtYXdqMjl0cFVpemxtZ3BaZTh5cTNQclFaR1doTjhHYjVLMg?oc=5", "source_name": "Investing.com", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp.'s (NASDAQ:BTMD) latest 10% decline adds to one-year losses, institutional investors may consider drastic measures", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-17T08:00:00+00:00", "published_display": "17 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Restructuring At Biote Will Drive Greater Growth And Profitability (NASDAQ:BTMD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxONEVUekVMY0w2eFVsemJqNGEzdTZEaVhaS2lnNmt3b3ZYUjRHRjA5UXFTaHh6NHc1Y0NCSC1SNndkdzNIMWN6aWtyZFNkWFBUTU5vcXltbHY2aklWRWFXMzF3QnpUb241YkN0NEQ2NUNmcThFX2VpakFTUElnWEluRlRrTjktQ1F0emk2RlFYVlJVem1mQ0hMOWVZSk9UTm9OQkRJbW5WeURaSUU?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-09-10T07:00:00+00:00", "published_display": "10 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "biote Corp. SEC 10-K Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNNXpqRmItblhWTElUa0VCSXRXVU1zSlVPZGU2M0FRWE4xUmZ0Q1RRV1VVM1Q2TGlVdDliVlV4X3VtXy1QYnoyMkNKaXg5dkVkYWZubm5DcGd6bEc1MWtxdnJmQkFQSmZZcG5DcGNrZFVkRHB0a3BVTUl5d0h6MFU0TWtPbkFiU3ZsMXhNdWpBQ21Odw?oc=5", "source_name": "TradingView", "published_at": "2025-03-14T07:00:00+00:00", "published_display": "14 Mar 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote settles founder's lawsuit by buying back his nearly $77 million in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNX3JzVFViMEU5SGxrM2lLVmhqbUNJLXp6ME5vSWt3YlVNdU5FS29sNDZiWlcwYU9neHhDby1za1dRNHQ4UmJMZjNQX2ZlUm1qTXhhX0FjbHRDaTMxOERxV3J4R3pURjlma0VCa0hpMlFka0plQV9INzJuczctOTFhRzRBUGRvUTZPU3U0VUFpVV84SUU4eThIT2lBZUl4YkI2bXBnZEZCSTJYeXNMZk9HMFRZeWFzT2J3bnlZX1RSMXhXcTM5eXZoZTFxeFhTMHZ5d1E?oc=5", "source_name": "Dallas News", "published_at": "2024-02-21T08:00:00+00:00", "published_display": "21 Feb 2024 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biote to be Listed on Nasdaq through a Business Combination with Haymaker Acquisition Corp. III", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQYW81QldwRGhILUZVZWxjRUJ0ek9ZRnhsRXZGNGVkbGlVb2ctSTJDYnktcTA4TjJmOUhYOUx4bDgtMW8xQU8wZFdsM19uaDFNVkJzNURQOS10TFJLYjB5LWVwMkRaam5xZV85c3JydmVLRkJGaU5yTEMtRHFINnVUX24tUzRNVGk4ek1vNTlxMG5BZXJjOFNKeVd5MjZrQ2hvMVlNZkg1dWxrckFkOGY4VUxrN2FaUzA?oc=5", "source_name": "IPO Edge", "published_at": "2021-12-13T13:30:03+00:00", "published_display": "13 Dec 2021 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 92, "total_relevant": 54, "sentiment_summary": {"positive": 5, "negative": 11, "neutral": 38, "score": 48, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 16.3, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 11}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.3, "count": 6}, {"event": "guidance", "label": "Guidance", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 5, "negative_events": 11}, "market_context": {"has_market_context": true, "latest_close": 2.33, "latest_week": "2026-07-10", "one_week_move": 7.4, "four_week_move": -5.3, "twelve_week_move": 5.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.914038, "market_dynamics_buy_signal": false, "relative_strength": -21.599341, "fair_value_gap": -47.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.0808, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.4% over one week, -5.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 18}, {"label": "TradingView", "count": 4}, {"label": "dars.gov.et", "count": 3}, {"label": "marketscreener.com", "count": 3}, {"label": "Market source", "count": 3}, {"label": "Simply Wall Street", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "Donan\u0131mHaber", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 11}, {"label": "Regulatory and legal", "count": 6}, {"label": "Guidance", "count": 4}, {"label": "Deals and strategy", "count": 2}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+7.4% over one week, -5.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to earnings forward of Biote Corp. \u2013 NASDAQ:BTMD"}], "updated_at": "2026-07-16T00:37:25.586853+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}